Company: DERM
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001410578-25-000490
Chunk: 19

Company: Journey Medical Corp
Filing Date: 2025-03-27
Form: 10-K
Item: Item 5M
Chunk 19
---
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market information

Our common stock is listed on the Nasdaq Capital Market and trades under the symbol “DERM.” We commenced trading on the Nasdaq Capital Market on November 12, 2021. Prior to November 12, 2021 there was no public market for our common stock. 

Equity Compensation Plans

Our board of directors has adopted an incentive plan, allowing for the grant of equity and cash-based awards to our employees and directors as well as a deferred compensation plan for non-employee members of the board of directors and select executive-level employees. We do not maintain any retirement, pension or profit-sharing plans. The additional information required by this item will be incorporated by reference from our definitive proxy statement to be filed with the SEC pursuant to Regulation 14A.

Sales of Unregistered Securities

None.

Use of Proceeds from Sales of Registered Securities

On December 30, 2022, we filed a shelf registration statement on Form S-3 (File No. 333 - 269079), which was declared effective by the SEC on January 26, 2023. This shelf registration statement covers the offering, issuance and sale by us of up to an aggregate of $150.0 million of the Company’s common stock, preferred stock, debt securities, warrants, and units (the “2022 Shelf”). In connection with the 2022 Shelf, we entered into an At Market Issuance Sales Agreement (the “Sales Agreement”) with B. Riley Securities, Inc. (“B. Riley”), relating to shares of our common stock. In accordance with the terms of the Sales Agreement, we may offer and sell up to 4,900,000 shares of our common stock, par value $0.0001 per share, from time to time through or to B. Riley acting as our agent or principal. From our entry into the Sales Agreement through December 31, 2024 , we issued and sold 2,313,013 shares of common stock under the 2022 Shelf, generating net proceeds of $12.8 million. At December 31, 2024, 2,586,987 shares remain available for issuance under the Sales Agreement.

We used and will continue to use the net proceeds from this offering for general corporate purposes, including working capital, research and development, payments for research and development — licenses acquired, sales and marketing